Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
According to an article just published on line in Prostate, taking statins before a diagnosis of prostate cancer lowers risk for prostate cancer-specific mortality (but does not lower risk for progression/recurrence of prostate cancer after first-line treatment). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, mortality, risk, statin | 2 Comments »
A new study, to published shortly on-line in Cancer, suggests that significant alterations to the “copy numbers” of the PTEN and MYC genes in men with prostate cancer are strongly associated with risk for prostate cancer-specific mortality. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: alteration, analysis, copy number, gene, mortality, MYC, PTEN, risk | 3 Comments »
A new study just published on line in the Journal of Clinical Oncology had confirmed that “BRCA1/2 mutations confer a more aggressive [prostate cancer] phenotype with a higher probability of nodal involvement and distant metastasis.” This is not a surprising finding, but it does have real implications for men with a family history of BRCA1/2 mutations. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: BRCA1, BRCA2, hereditary, mortality, risk, survival | 8 Comments »
There has been significant media coverage of a recent article in the journal Circulation. The article reports that individuals enrolled in the Atherosclerosis Risk in Communities (ARIC) study were able to cut their overall risk for cancer by 51 percent. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Tagged: cancer, cardiovascular, Diagnosis, diet, lifestyle, mortality, risk | Leave a Comment »
Just over a month ago we mentioned the CSQS in commenting on a Swedish paper (by Eloranta et al.) that dealt with prediction of the “crude” or “real world” probability of death from prostate cancer (as opposed to potential, competing causes of death). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, mortality, prognosis, risk, survival, Treatment | Leave a Comment »
As we age, and have to consider the risks and benefits of all sorts of health-related issues, it is often both helpful and important to have a clear and reasonable idea of how long we might expect to live. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 10-year, index, mortality | 1 Comment »
The Prostate Cancer Prevention Trial (PCPT) showed that treatment with finasteride (a 5α-reductase inhibitor) could lower the number of prostate cancers diagnosed in the U.S. each year by about 25 percent. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: death, finasteride, mortality, PCPT, Prevention, survival | 5 Comments »
Imagine that you are 65 years of age and have just been diagnosed with intermediate-risk prostate cancer (clinical stage T1c; PSA 3.7 ng/ml; Gleason 3 + 4 = 7; with 3/12 biopsy cores positive for cancer, all in the left lobe). You understand quickly that this places you at some risk for progressive disease, and perhaps even for prostate cancer-specific mortality. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: death, Diagnosis, mortality, prognosis, risk, survival | 11 Comments »
According to the newly published report, “Cancer statistics, 2013,” now available in the journal CA: A Cancer Journal for Clinicians, prostate cancer will become the most commonly diagnosed cancer of any type in the USA this year. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: 2013, estimate, incidence, mortality | 3 Comments »
We don’t want to get into the details (which are covered extensively in other sources), but a study published today in the New England Journal of Medicine, and encompassing the entire population of Denmark, suggests that people with cancer who take a statin (a cholesterol-lowering agent) have a 15 percent lower mortality rate than cancer patients not taking a statin. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: Denmark, mortality, statin | Leave a Comment »
The vast majority of prostate cancers are adenocarcinomas of the prostate, i.e., cancers that start in the epithelial cells of the prostate gland. Most of these adenocarcinomas have a well-defined, “normal” cancer histology. However, there are five categories of rare adenocarcinoma, with differing levels of risk. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: adenocarcinoma, incidence, mortality, rare, subtype | Leave a Comment »
A study based on the CaPSURE database, and just published in the Journal of Oncology, has again suggested that prostate cancer patients who are regular users of anticoagulant are a lower risk of prostate cancer-specific mortality than non-aspirin users. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: anticoagulant, aspirin, cancer-specific, mortality | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site